The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwHRMM 2025 | Strategies being explored to optimize CAR T-cell therapy for high-risk multiple myeloma
In this video, Doris Hansen, MD, Moffitt Cancer Center, Tampa, FL, briefly discusses the current strategies being explored to optimize CAR T-cell therapy for high-risk multiple myeloma (MM), including maintenance, consolidation, and debulking approaches. This interview took place at the 2nd International Workshop on High-Risk Multiple Myeloma (iwHRMM 2025), held in Charleston, SC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
There are multiple strategies ongoing. There are maintenance and consolidation strategies. There’s maintenance with immunomodulatory drugs and even CELMoDs, certainly in clinical trials, there are consolidative strategies, particularly with bispecifics. Generally, same or different target, though more different target approaches. A very nice consolidation study was presented at IMS last month by Adam Cohen, where cevostemab was utilized as consolidation post-BCMA CAR-T with ide-cel and cilta-cel that has shown promising results with early follow-up...
There are multiple strategies ongoing. There are maintenance and consolidation strategies. There’s maintenance with immunomodulatory drugs and even CELMoDs, certainly in clinical trials, there are consolidative strategies, particularly with bispecifics. Generally, same or different target, though more different target approaches. A very nice consolidation study was presented at IMS last month by Adam Cohen, where cevostemab was utilized as consolidation post-BCMA CAR-T with ide-cel and cilta-cel that has shown promising results with early follow-up. So certainly beyond consolidation and maintenance, debulking strategies such as bridging to debulk the disease, but also hopefully alter and improve the immune microenvironment are also some important considerations to enhance efficacy of CAR T-cell products for multiple myeloma.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
